Biotechnology - Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
5/6/2008 12:30:00 PM
[NEWS]SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ — CatalystBiosciences, Inc., a pioneer in the discovery and development of engineeredproteases known as Alterase™ therapeutics, announced that it hasselected CB 813, an improved, second-generation variant of humancoagulation factor VIIa, as a development candidate for the treatment ofacute bleeding in hemophilia patients. CB 813 was created using Catalyst’sproprietary therapeutic protease platform technologies and know-how. CB 813 is des…
...
full article